Karen Flynn, Director at Recro Pharma, Inc. (REPH), bought 800 shares at $6.71 ($5K) on 2016-12-16, disclosed to the SEC on 2016-12-19.
Open-market purchase of $5k REPH by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| CTLT | SELL | 2021-01-11 | $433K | — | Filing → |
| CTLT | SELL | 2021-01-05 | $10K | — | Filing → |
| WST | SELL | 2018-08-09 | $4.8M | — | Filing → |